PURPOSE: Stereotactic radiotherapy (SRT) is highly effective for brain metastases from @entity1149 ( @entity1149 ). As such, primary lesions of NSCLC may also be treated effectively by similar focal high-dose SRT. METHODS AND MATERIALS: Between October 1994 and June 1999, 50 @entity1 with pathologically proven T1-2N0 M0 NSCLC were treated by CT-guided frameless SRT. Of these, 21 @entity1 were medically inoperable and the remainder were medically operable but refused surgery. In most @entity1 , SRT was 50-60 Gy in 5-10 fractions for 1-2 weeks. Eighteen @entity1 also received conventional radiotherapy of 40-60 Gy in 20-33 fractions before SRT. RESULTS: With a median follow-up period of 36 months (range 22-66), 30 @entity1 were alive and disease free, 3 were alive with disease, 6 had died of disease, and 11 had died intercurrently. Local progression was not observed on follow-up CT scans in 47 (94%) of 50 @entity1 . The 3-year overall survival rate was 66% in all 50 @entity1 and 86% in the 29 medically operable @entity1 . The 3-year cause-specific survival rate of all 50 @entity1 was 88%. No definite adverse effects related to SRT were noted, except for 2 @entity1 with a minor @entity174 and 6 @entity1 with temporary @entity158 . CONCLUSIONS: SRT is a very safe and effective treatment for Stage I NSCLC. Additional studies involving a larger @entity1 population and longer follow-up periods are warranted to assess this new treatment for @entity5 .

Computed tomography-guided frameless stereotactic radiotherapy for stage I XXXX : a 5-year experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity174 :: ('MESH:D050723', 'Disease') :: ['bone fracture'] @entity5 :: ('MESH:D009369', 'Disease') :: ['early-stage lung cancer'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small-cell lung cancers', 'NSCLCs'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pleural pain']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
